Life science news and medical media coverage for healthcare professionals
Critical Care10 Sept 2026
E-scooter head injuries: Why are urban trauma centers seeing more?Read article
Why are we still treating cancer prevention as adjunctive care?
Adopting a healthy lifestyle correlates with reduced risk for 13 distinct cancer types, highlighting the role of modifiable factors in oncology.
Multicancer tests: Can we screen without knowing the outcome?
An FDA panel recently reviewed multicancer early detection tests, highlighting significant data gaps regarding their clinical utility and impact on patient outcomes.
Brain metastases: Why less radiation, more often, improves outcomes
Multi-fraction stereotactic radiotherapy reduces local failure and radiation necrosis in resectable brain metastases compared to single-fraction approaches.
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Salivary gland cancer: Is HER2-low the new HER2-positive?
Multicancer early detection: Can we screen for what we can't treat?
Lung cancer in never smokers: The 60x risk factor you might be missing
Chemo hair loss: Why some patients feel it more deeply
Breast cancer home injections: Convenient for patients, complex for insurers
Seladelpar and elafibranor: second-line options for PBC
For patients with primary biliary cholangitis (PBC) who do not respond adequately to ursodeoxycholic acid, seladelpar and elafibranor offer new therapeutic avenues.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Seladelpar and elafibranor offer new therapeutic avenues for primary biliary cholangitis patients with inadequate response to ursodeoxycholic acid.
ACLF: Why G-CSF works for some, but fails others
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Liver disease: Is coffee a daily dose of prevention?
Why primary sclerosing cholangitis remains a therapeutic graveyard
GLP-1s: Is eligibility missing half your high-risk patients?
A 313,000-person Danish and UK analysis finds people with a BMI of 25-26.9, currently ineligible for GLP-1 receptor agonists, have coronary heart disease risk matching those who do qualify, if they also carry elevated remnant cholesterol or inflammation.
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Evolocumab, a PCSK9 inhibitor, has demonstrated a potential to reduce the risk of death in patients at high cardiovascular risk, offering a critical addition to lipid-lowering strategies.
Endocarditis: Why fixed-dose ampicillin often misses the mark
A personalized antibiotic strategy, guided by therapeutic drug monitoring, optimizes ampicillin regimens in enterococcal bloodstream infections and endocarditis.
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Hypertension: Do shorter wall squats work as well for older women?
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Tactical athletes need more than a sports physical
Peripheral arterial disease: Why early detection still eludes us
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Type 1 diabetes screening: Why one protocol worked across 8 nations
EDENT1FI tested 140,568 young people and found early-stage type 1 diabetes in about 1 in 45 with a relative and 1 in 350 without, across 8 countries.
Survodutide: Is 9.8% weight loss enough for its GI cost?
SYNCHRONIZE-2 in NEJM: survodutide 6.0 mg cut weight 9.8% versus 3.9% on placebo over 76 weeks in type 2 diabetes, but about 1 in 4 stopped treatment.
Marathon running with type 1 diabetes: Is it finally safe?
Adults with type 1 diabetes can safely complete marathons by leveraging continuous glucose monitoring (CGM) and traditional glucometers for real-time glucose management.
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Bariatric surgery: The hidden hernia risk you're missing
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
CBL-514: Is visceral fat reduction the real story?
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Tau hyperphosphorylation impairs cooperative binding to microtubules and disrupts lysosome trafficking in neurons, mimicking tau knockout effects.
Fibromyalgia: Is the pain real if the tissue damage isn't?
Fibromyalgia is increasingly understood as a central nervous system disorder, not a peripheral tissue disease, challenging traditional diagnostic approaches.
Routine childhood vaccines: Less coverage means more than just infections
Lifelong odor sensitivity: What early exposure means for your patients?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
Spike sorting: Is your 'black box' holding back neural insights?
Can mice learn to control their own brains? A new neurofeedback system
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
AdvertisementAdvertisement
• Oct 21 – 23ESMO 2026 • Madrid, ES 
• Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEJoint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12Advertisement
Advertisement
TorontoOct 21 – 23 2026Get on-site reporting the moment it publishes.
TorontoAttending Joint ACTRIMS-ECTRIMS 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
